A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis

两性霉素B 医学 伊曲康唑 两性霉素B脱氧胆酸盐 内科学 外科 胃肠病学 置信区间 临床试验 抗真菌 皮肤病科 卡斯波芬金
作者
Thuy Le,Nguyễn Văn Kính,Ngo Thi Kim Cuc,Nguyen Le Nhu Tung,Nguyễn Thị Lâm,Pham Thanh Thuy,Cuong Duy,Pham T.H. Phuc,Vinh Vu Hai,Doan Thi Hong Hanh,Vu Van Tam,Nguyen Tat Thanh,Tran Phuong Thuy,Nguyen T Hang,Long Bao Hoang,Ho Thi Nhan,Heiman Wertheim,Laura Merson,Cecilia M. Shikuma,Jeremy Day
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:376 (24): 2329-2340 被引量:164
标识
DOI:10.1056/nejmoa1613306
摘要

Talaromyces marneffei infection is a major cause of human immunodeficiency virus (HIV)-related death in South and Southeast Asia. Guidelines recommend initial treatment with amphotericin B deoxycholate, but this drug has substantial side effects, a high cost, and limited availability. Itraconazole is available in oral form, is associated with fewer unacceptable side effects than amphotericin, and is widely used in place of amphotericin; however, clinical trials comparing these two treatments are lacking.In this open-label, noninferiority trial, we randomly assigned 440 HIV-infected adults who had talaromycosis, confirmed by either microscopy or culture, to receive either intravenous amphotericin B deoxycholate (amphotericin) (219 patients), at a dose of 0.7 to 1.0 mg per kilogram of body weight per day, or itraconazole capsules (221 patients), at a dose of 600 mg per day for 3 days, followed by 400 mg per day, for 11 days; thereafter, all the patients received maintenance therapy with itraconazole. The primary outcome was all-cause mortality at week 2. Secondary outcomes included all-cause mortality at week 24, the time to clinical resolution of talaromycosis, early fungicidal activity, relapse of talaromycosis, development of the immune reconstitution inflammatory syndrome (IRIS), and the side-effect profile.The risk of death at week 2 was 6.5% in the amphotericin group and 7.4% in the itraconazole group (absolute risk difference, 0.9 percentage points; 95% confidence interval [CI], -3.9 to 5.6; P<0.001 for noninferiority); however, the risk of death at week 24 was 11.3% in the amphotericin group and 21.0% in the itraconazole group (absolute risk difference, 9.7 percentage points; 95% CI, 2.8 to 16.6; P=0.006). Treatment with amphotericin was associated with significantly faster clinical resolution and fungal clearance and significantly lower rates of relapse and IRIS than itraconazole. The patients who received amphotericin had significantly higher rates of infusion-related reactions, renal failure, hypokalemia, hypomagnesemia, and anemia than patients in the itraconazole group.Amphotericin was superior to itraconazole as initial treatment for talaromycosis with respect to 6-month mortality, clinical response, and fungicidal activity. (Funded by the Medical Research Council and others; IVAP Current Controlled Trials number, ISRCTN59144167 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
庞晓丽发布了新的文献求助30
2秒前
Lizhihong发布了新的文献求助10
2秒前
2秒前
FaFa发布了新的文献求助10
3秒前
铁锤牛马版举报toosweet的求助涉嫌违规
3秒前
4秒前
Joanna完成签到,获得积分10
4秒前
lorentzh完成签到,获得积分10
4秒前
6秒前
天天发布了新的文献求助10
6秒前
qunqing发布了新的文献求助10
8秒前
大气幻柏发布了新的文献求助10
8秒前
爆米花的应助被Kyra采纳,获得10
9秒前
9秒前
科目三的应助被楠楠采纳,获得10
10秒前
11秒前
LuXiaoyu的应助被cookie采纳,获得10
11秒前
炸炸炸完成签到 ,获得积分10
11秒前
maguodrgon发布了新的文献求助10
11秒前
LuckyYu发布了新的文献求助10
12秒前
13秒前
斯文败类的应助被科研通管家采纳,获得10
13秒前
13秒前
ding的应助被科研通管家采纳,获得10
13秒前
科目三的应助被科研通管家采纳,获得30
13秒前
13秒前
13秒前
上官若男的应助被科研通管家采纳,获得10
14秒前
可咳咳咳完成签到,获得积分10
14秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
14秒前
cdercder的应助被科研通管家采纳,获得10
14秒前
小蘑菇的应助被科研通管家采纳,获得10
14秒前
丘比特的应助被科研通管家采纳,获得10
14秒前
Hello的应助被科研通管家采纳,获得10
14秒前
14秒前
14秒前
Qqqq完成签到 ,获得积分10
14秒前
搜集达人的应助被科研通管家采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188210
求助须知:如何正确求助?哪些是违规求助? 9576001
关于积分的说明 21844898
捐赠科研通 7786081
什么是DOI,文献DOI怎么找? 3435220
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482139